Literature DB >> 20153122

Disturbed colonic motility contributes to anorectal symptoms and dysfunction after radiotherapy for carcinoma of the prostate.

Eric K Yeoh1, Dylan L Bartholomeusz, Richard H Holloway, Robert J Fraser, Rochelle Botten, Addolorata Di Matteo, James W Moore, Mark N Schoeman.   

Abstract

PURPOSE: To evaluate the role of colonic motility in the pathogenesis of anorectal symptoms and dysfunction after radiotherapy (RT) for carcinoma of the prostate. PATIENTS AND METHODS: Thirty-eight patients, median age 71 (range, 50-81) years with localized prostate carcinoma randomized to one of two radiation dose schedules underwent colonic transit scintigraphy and assessment of anorectal symptoms (questionnaire), anorectal function (manometry), and anal sphincteric morphology (endoanal ultrasound) before and at 1 month and 1 year after RT.
RESULTS: Whole and distal colonic transit increased 1 month after RT, with faster distal colonic transit only persisting at 1 year. Frequency and urgency of defecation, fecal incontinence, and rectal bleeding increased 1 month after RT and persisted at 1 year. Basal anal pressures remained unchanged, but progressive reductions occurred in anal squeeze pressures and responses to increased intra-abdominal pressure. Rectal compliance decreased progressively in the patients, although no changes in anorectal sensory function ensued. Radiotherapy had no effect on the morphology of the internal and external anal sphincters. Distal colonic retention was weakly related to rectal compliance at 1 month, but both faster colonic transit and reduced rectal compliance were more frequent with increased fecal urgency. At 1 year, a weak inverse relationship existed between colonic half-clearance time and frequency of defecation, although both faster whole-colonic transit and reduced rectal compliance occurred more often with increased stool frequency.
CONCLUSION: Colonic dysmotility contributes to anorectal dysfunction after RT for carcinoma of the prostate. This has implications for improving the management of anorectal radiation sequelae.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20153122     DOI: 10.1016/j.ijrobp.2009.08.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

Review 2.  Systematic review: anal and rectal changes after radiotherapy for prostate cancer.

Authors:  Robin Krol; Robert Jan Smeenk; Emile N J T van Lin; Eric E K Yeoh; Wim P M Hopman
Journal:  Int J Colorectal Dis       Date:  2013-10-23       Impact factor: 2.571

3.  Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough?

Authors:  M Bonet; L Cayetano; M Núñez; E Jovell-Fernández; A Aguilar; Y Ribas
Journal:  Clin Transl Oncol       Date:  2017-09-12       Impact factor: 3.405

4.  Can Anorectal Manometry Findings Predict Subsequent Late Gastrointestinal Radiation Toxicity in Prostate Cancer Patients?

Authors:  Yunseon Choi; Won Park; Poong-Lyul Rhee
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679

5.  Rectal prolapse traumatizes rectal neuromuscular microstructure explaining persistent rectal dysfunction.

Authors:  Matthias Kraemer; Werner Paulus; David Kara; Saskia Mankewitz; Stephanie Rozsnoki
Journal:  Int J Colorectal Dis       Date:  2016-09-06       Impact factor: 2.571

6.  Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review.

Authors:  Paul Sargos; Mame Daro Faye; Manon Bacci; Stéphane Supiot; Igor Latorzeff; David Azria; Tamim M Niazi; Te Vuong; Véronique Vendrely; Renaud de Crevoisier
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.